Kratom has been sold openly in gas stations, smoke shops, and vape stores across the country. But a newer product on those same shelves is not really kratom at all. It is 7-hydroxymitragynine, usually labeled as 7-OH, and the FDA has identified it as a concentrated opioid that poses a serious public health threat.
The confusion is understandable. 7-OH does occur naturally in the kratom plant, but only as a minor alkaloid that makes up less than 2% of the leaf. The products being sold today are different. They are extracted, concentrated, and in some cases enriched to levels far beyond anything found in nature. That distinction is the heart of the 7-OH vs kratom question, and it matters because the risks are not the same.
This guide explains what 7-OH is, how it compares to traditional kratom, why federal regulators are moving to restrict it, and what to do if you or someone you love is struggling with dependence on either substance.
Kratom and Its Alkaloids: The Chemical Foundation
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia. For centuries, workers in countries like Thailand and Malaysia have chewed its leaves to manage fatigue and physical discomfort. The leaf contains more than 50 active compounds called alkaloids, but two get most of the attention because they drive most of kratom’s opioid-like effects: mitragynine and 7-hydroxymitragynine (7-OH).
Mitragynine is by far the more abundant of the two. It can make up as much as 66% of the total alkaloid content in some kratom varieties, though the exact share depends on where the plant is grown. 7-OH, on the other hand, is a trace compound. The FDA reports that 7-OH makes up less than 2% of the total alkaloid content in natural kratom leaves, and other research puts it at less than 0.02% of the dry leaf by weight.
Here is the key point: that tiny amount of 7-OH carries an outsized punch. It is dramatically more potent for the brain’s opioid receptors than mitragynine is, and that gap between how much 7-OH exists in the leaf and how strong it actually is sits at the center of the 7-OH vs kratom problem.
Both alkaloids attach to the same opioid receptors in the brain (the mu-opioid receptors, the same targets used by morphine, oxycodone, and other classical opioids), but they do not act on those receptors with the same force. Mitragynine is generally described as a partial agonist. It turns those receptors on, but only partway, which produces weaker euphoric effects and substantially less respiratory depression than a full opioid like morphine or oxycodone.
7-OH activates the same receptors with much greater efficacy and binding strength, and although it is also technically a partial agonist, its functional behavior is closer to a classical opioid than mitragynine’s is. That is why the FDA’s 2025 scientific assessment characterizes concentrated 7-OH products as opioids and has formally recommended they be scheduled as controlled substances at the federal level.
What Is 7-Hydroxymitragynine, Exactly?
7-hydroxymitragynine is a real, naturally occurring alkaloid in the kratom plant. The problem is that you almost never run into it at any meaningful concentration if you are using raw kratom leaf. It is a trace compound. What is being sold today as 7-OH is something different. These are processed products that concentrate, isolate, or semi-synthesize the alkaloid far beyond anything the plant itself produces.
You will see these products under labels like 7-OH tablets, 7-OH shots, 7-OH drink shots, 7-OH gummies, novelty packaging shaped like ice cream cones, and concentrated 7-OH extract pills. They show up in gas stations, smoke shops, vape stores, wellness shops, and online retailers across most of the United States, often sitting on the same shelf as traditional kratom powder.
A study published in the Journal of Medicinal Chemistry (Takayama et al.) found that 7-hydroxymitragynine was a more potent opioid agonist than morphine in guinea pig ileum tests; researchers reported it as roughly 13 times more potent than morphine and 46 times more potent than mitragynine in those lab assays. Those are pre-clinical animal-tissue results, not human dosing equivalents, and the real-world translation depends on the route of administration, the dose, and the individual. But the trend across multiple studies is consistent. The FDA’s assessment found that 7-OH causes respiratory depression with more than three times the potency of morphine in animal test subjects.
The practical takeaway: regular kratom leaf tends to act more like a stimulant at low doses, with opioid-like effects emerging mainly at higher doses. Concentrated 7-OH behaves more like a strong synthetic opioid from the start, and that is a clinically meaningful difference for anyone using these products.
7-OH vs Kratom: The Potency Gap Explained
The difference between mitragynine and 7-OH is not just a question of “stronger or weaker.” It reflects two different opioid pharmacodynamics that carry very different risks. Consider the following comparison table to fully understand the potency gap:
| FEATURE | REGULAR KRATOM LEAF | 7-OH |
| Primary Alkaloid Profile
| Mitragynine dominant
| 7-OH dominant (isolated/concentrated)
|
| Receptor Binding Affinity
| Moderate binding to mu-opioid receptors
| Significantly tighter, stronger mu-opioid binding
|
| Dose-Dependent Effects | Low doses: Stimulant-like effects High doses: Sedative, opioid-like effects
| Consistently produces heavy sedation, pain relief, and intense euphoria
|
| The “Ceiling Effect”
| Present; higher doses plateau rather than infinitely intensifying effects
| Absent; effects continue to escalate linearly with the dosage
|
| Respiratory Depression Risk
| Low; breathing suppression hits a distinct safety ceiling at higher doses
| High; breathing suppression is dose-dependent, scaling upward like traditional opioids British Journal of Pharmacology (Hill et al.)
|
| Overdose Profile
| Lower risk on its own; risk increases sharply when mixed with other depressants
| Higher, traditional opioid-like risk due to progressive respiratory suppression
|
This is not a theoretical concern. The FDA has issued multiple public health advisories on kratom and 7-OH products, and medical examiners have documented deaths involving kratom compounds. Most of these deaths have involved polysubstance use (using more than one drug or substance within a short period) or concentrated extracts. The San Francisco Department of Public Health recently flagged 6 overdose deaths in Los Angeles tied to synthetic 7-OH alone. The risk goes up sharply when 7-OH is combined with alcohol, benzodiazepines, or other central nervous system depressants.
Why Concentrated 7-OH Products Carry Serious Addiction Risks
Physical dependence on kratom is well-documented. People who use it regularly, especially at higher doses, often report withdrawal symptoms that look a lot like opioid withdrawal: muscle aches, insomnia, irritability, nausea, sweating, runny nose, restlessness, and intense cravings. Those symptoms make sense once you understand how kratom acts on the opioid system. Both mitragynine and 7-OH attach to the brain’s mu-opioid receptors, and the brain adapts, over time, to repeated activation of those receptors. When the drug is suddenly removed, the system rebounds.
7-OH addiction tends to develop faster and hit harder than dependence on plain kratom leaf. The University of Virginia Department of Toxicology explains it directly: because 7-OH is so much more potent at the mu-opioid receptor than mitragynine, dependence is more likely to develop with chronic 7-OH use than with kratom leaf. A 2025 peer-reviewed research on 7-OH echoes the same finding. Animal studies of 7-OH consistently show tolerance and dependence, and the kind of reinforcing properties you see with classical opioids.
The pharmacology behind this is straightforward. Stronger opioid receptor activation drives stronger adaptation in the brain’s reward system. The deeper that adaptation goes, the more uncomfortable the rebound is when the substance is taken away. That is also why 7-OH withdrawal often does not respond to the same approaches that work for someone tapering off plain-leaf kratom.
Clinically, people who develop dependence on concentrated 7-OH products often need more structured care than those who used only kratom leaf. Standard outpatient tapering may not be enough. If you or someone you know is dealing with 7-OH or kratom dependence, talking with a medical professional about the right level of care is the safest next step. Freeman Recovery Center’s clinical team evaluates your full substance use history before recommending a care plan, including whether medically supervised detox is appropriate. Contact us today.
The Legal and Regulatory Status of 7-OH
The legal status of 7-OH is complicated and changing fast, especially in the past two years. At the federal level, kratom itself is not currently a controlled substance, though the DEA has come close. In August 2016, the DEA proposed scheduling mitragynine and 7-OH as Schedule I, then withdrew that proposal in October 2016 after significant public pushback.
The situation for 7-OH specifically has shifted dramatically since then. On January 22, 2025, the DEA officially designated kratom and 7-OH as “Drugs of Concern.” On July 29, 2025, the FDA formally recommended that concentrated 7-OH products be scheduled as Schedule I under the Controlled Substances Act. The FDA also issued warning letters to seven companies marketing 7-OH products in July 2025 and announced direct seizures of 7-OH inventory in December 2025.
At the state level, the map keeps shifting. As of May 2026, seven states have banned kratom outright: Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, and Wisconsin. Rhode Island previously had a ban but reversed it on April 1, 2026, replacing prohibition with a regulated framework. Florida shows a different pattern. It has a Kratom Consumer Protection Act on the books that keeps natural kratom legal, but in August 2025 the state attorney general issued an emergency rule scheduling concentrated 7-OH specifically as a Schedule I substance, separate from kratom itself.
Tennessee has had its own kratom regulatory history. State law (Tenn. Code Ann. § 39-17-452) has scheduled synthetic mitragynine and 7-OH as controlled substances since 2014. A 2017 amendment clarified that natural kratom from Mitragyna speciosa was legal for adults 21 and older. That two-track system stayed in place for almost a decade, with the synthetic forms illegal and the natural leaf legal under age restrictions. That ends on July 1, 2026. On April 16, 2026, Governor Bill Lee signed HB1649, known as Matthew Davenport’s Law, into law. The bill enacts a full ban on kratom in all forms, including concentrated 7-OH. After July 1, 2026, possession will be a Class A misdemeanor and manufacture or sale will be a Class C felony.
Beyond the bans and recommendations, the bigger immediate problem is what is on the market right now. Consumers have very little guarantee about the potency or purity of what they buy. Third-party lab testing is inconsistent across the industry, and some products marketed simply as “kratom” actually contain 7-OH concentrations far beyond anything the leaf could produce on its own. Legal availability is not the same as safety, and as the past 18 months have shown, legal availability can change very quickly.
What Dependence on 7-OH Actually Looks Like
Tolerance to 7-OH builds faster than tolerance to plain kratom leaf, and that drives a predictable pattern. What starts as occasional use for pain, anxiety, or energy can shift to daily use surprisingly quickly. As tolerance climbs, doses go up, frequency goes up, and the gap between doses starts to come with real physical and psychological discomfort. Many people who end up dependent on high-potency 7-OH products thought they were using a natural supplement with low addiction risk. That belief is widespread, and the pharmacology does not back it up.
7-OH withdrawal looks a lot like opioid withdrawal. Onset typically begins somewhere in the first 6 to 24 hours after the last dose, though it can come on faster in people using high-dose concentrated extracts than in people who stuck to traditional leaf. The acute phase usually lasts several days to a week, with some symptoms lingering longer. The symptom picture includes muscle cramps, restless legs, insomnia, sweating, runny nose, diarrhea, nausea, anxiety, low mood, and strong cravings. These overlap closely with the symptoms of withdrawal from prescription opioids, which is one of the reasons clinicians often borrow from established opioid withdrawal protocols when treating 7-OH dependence. The University of Virginia Department of Toxicology notes that 7-OH withdrawal management mirrors standard opioid withdrawal care.
There are no FDA-approved medications for treating 7-OH or kratom withdrawal. Care is largely supportive: hydration, medications to manage individual symptoms (nausea, sleep, blood pressure, anxiety), and, in some cases, short-term use of buprenorphine or similar medications under medical supervision.
Mental health is part of the picture, too. The FDA notes that people commonly use kratom to self-treat conditions like anxiety, depression, and opioid use disorder. For someone who started using kratom or 7-OH to manage an untreated substance use or mental health disorder, withdrawal can hit harder. Anxiety, depression, and PTSD symptoms often get worse before they get better, which raises the relapse risk if the underlying condition is not addressed at the same time. Dual diagnosis care that treats both the substance use and the underlying mental health condition is often the most effective path. Freeman Recovery Center’s dual diagnosis program is built around that overlap, recognizing that many people reach for kratom or 7-OH because something else was already going on.
Signs That 7-OH Use Has Crossed into Dependence
Not everyone who uses kratom or 7-OH needs inpatient care. But some patterns are clear signals that a professional evaluation is the right next step.
The clinical criteria for substance use disorder are well established. The FDA explicitly recognizes that people who use kratom can meet substance use disorder criteria, and peer-reviewed research has applied DSM-5 criteria to both kratom and 7-OH dependence. The signs to watch for are the same ones used to diagnose other substance use disorders:
-
Daily Compulsion & Distress: Using 7-OH every day and experiencing significant mental or emotional distress if you cannot access it
-
Building Tolerance: Needing increasingly larger or more frequent doses to achieve the initial desired effect
-
Physical Withdrawal: Experiencing uncomfortable physical or psychological symptoms when you attempt to cut back or stop
-
Persistent Use Despite Harm: Continuing to take the substance despite noticeable damage to your health, relationships, career, or finances
-
Loss of Control: Making repeated, unsuccessful attempts to quit or reduce your dosage on your own
A medical evaluation can help figure out what level of support actually fits. For some, that means medically-supervised detox. For others, structured outpatient care or a partial hospitalization program is the right starting point. 7-OH addiction is a real, clinically-recognized condition. Like other opioid-related substance use disorders, it responds to evidence-based treatment. Learn more about treatment for kratom addiction here.
Frequently Asked Questions About 7-OH
What is 7-hydroxymitragynine and how is it different from kratom?
7-hydroxymitragynine, or 7-OH, is one of the alkaloids found naturally in the kratom plant, but only in trace amounts (less than 2% of the total alkaloid content of the leaf). The important difference is potency. 7-OH binds much more strongly to the brain’s opioid receptors than mitragynine, the main kratom alkaloid. The concentrated 7-OH products sold today (tablets, shots, gummies, extracts) contain far more 7-OH than the leaf itself ever could, which is why the FDA treats them as opioids rather than as kratom.
Is 7-OH kratom legal in the United States?
It depends where you are, and the answer keeps changing. Federally, kratom and 7-OH are not yet scheduled controlled substances, though the FDA formally recommended in July 2025 that concentrated 7-OH be classified as Schedule I. As of May 2026, seven states ban kratom (and 7-OH along with it): Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, and Wisconsin. Tennessee will join that list on July 1, 2026 under Matthew Davenport’s Law (HB1649). Legal availability is not the same as safety, and 7-OH is the part of the kratom market regulators are moving fastest to restrict.
Why is 7-OH considered more dangerous than regular kratom?
Because it acts much more like a traditional opioid. 7-OH binds mu-opioid receptors far more tightly than mitragynine does, and in animal studies, it has been reported as roughly 13 times more potent than morphine. That stronger receptor activation drives faster tolerance, higher dependence risk, and meaningful respiratory depression, which is especially dangerous when 7-OH is combined with alcohol, benzodiazepines, or other depressants.
Can you get physically dependent on 7-hydroxymitragynine?
Yes. Because 7-OH activates the brain’s opioid receptors so strongly, dependence can develop faster than it does with plain kratom leaf, and withdrawal often hits harder. The symptom picture looks a lot like opioid withdrawal: muscle aches, insomnia, sweating, nausea, anxiety, and strong cravings.
What level of care is appropriate for 7-OH dependence?
It depends on several factors: how long someone has been taking kratom, the doses involved, whether there are co-occurring mental health disorders like anxiety or depression, and whether treatment has been attempted before. For some people, intensive outpatient care is enough. Others do better starting with medically-supervised detox followed by residential or partial hospitalization treatment.
The most reliable way to know what fits is a clinical assessment with a licensed, professional treatment team. At Freeman Recovery Center, that assessment is free and confidential, and it covers both the substance use and any mental health concerns that may be contributing to it.
